Showing results (1241-1250 of 1,293) with videos related to

Sort By:
Pageof 130
Journal of Medicinal Chemistry|April 25, 2012
Structure-based design of novel inhibitors of the MDM2-p53 interactionYosup Rew, Daqing Sun, Felix Gonzalez-Lopez De Turiso, et al.
Rheumatology (Oxford, England)|January 22, 2020
Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14 868 patients with spondyloarthritisBrigitte Michelsen, Lykke Midtbøll Ørnbjerg, Tore K Kvien, et al.
Scientific Reports|February 7, 2015
Convergence of soil nitrogen isotopes across global climate gradientsJoseph M Craine, Andrew J Elmore, Lixin Wang, et al.
Seminars in Arthritis and Rheumatism|February 1, 2024
Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practiceSara Nysom Christiansen, Simon Horskjær Rasmussen, Marion Pons, et al.
Ecology Letters|June 5, 2007
Global negative vegetation feedback to climate warming responses of leaf litter decomposition rates in cold biomesJohannes H C Cornelissen, Peter M van Bodegom, Rien Aerts, et al.
The Journal of Rheumatology|June 15, 2026
Overall and sex-specific predictors of secukinumab effectiveness in European patients with psoriatic arthritis: results from the EuroSpA collaborationJette Heberg, Stylianos Georgiadis, Zohra Ahmadzay, et al.
Joint Bone Spine|November 28, 2024
Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritisMarion Pons, Stylianos Georgiadis, Mikkel Østergaard, et al.
The Lancet Regional Health. Europe|August 21, 2023
Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across EuropeBrigitte Michelsen, Mikkel Østergaard, Michael John Nissen, et al.
The Journal of Rheumatology|December 1, 2022
One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor TreatmentLykke Midtbøll Ørnbjerg, Kathrine Rugbjerg, Stylianos Georgiadis, et al.
Arthritis Care & Research|January 18, 2021
Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European CountriesBrigitte Michelsen, Stylianos Georgiadis, Daniela Di Giuseppe, et al.
Pageof 130